

Because patients' health cannot wait :

Leem focuses its action on access to therapeutic progress for patients and on France's economic vitality

Leem's Board of Directors met on Wednesday 14 January 2026 to set out the next stages of its work and organise the continuation of its action, on behalf of its 260 member companies of all sizes, operating across the entire country and throughout the full pharmaceutical value chain.

Board members unanimously emphasised the need for Leem to remain united in order to address the challenges facing the sector and the healthcare system, in an unprecedented geopolitical and budgetary context .

At this pivotal moment, Leem is firmly committed to making patients' access to therapeutic innovation a top priority, recognising it as a key driver of France's economic vitality. This is a public health imperative.

The upcoming milestones — budgetary, with the preparation of the 2027 Social Security Financing Act (PLFSS), and political, notably with the presidential election — will be decisive. Without ambitious and impactful reforms, access to current and future medicines will no longer be guaranteed, and France will no longer rank among the world's leading scientific and industrial healthcare powers. As the representative trade association for pharmaceutical companies, Leem will take its full part in the debates.

The Board of Directors has therefore decided to adapt Leem's operating models and has immediately launched the necessary work, while continuing to fully assume its role as a representative trade association.

"Because patients' health cannot wait and must not be undermined by divisions within the sector, Leem and its member companies are more mobilised than ever," said Thierry Hulot, President of Leem.

Contacts Presse : Virginie PAUTRE - 06 31 86 82 70 - vautre@leem.org / Julien GOUGEROT - 06 08 97 50 49 jgougerot@leem.org

Direction de la Communication : Stéphanie Bou -06 60 46 23 08 - sbou@leem.org